Mobile App

Google Play Apple Store
Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO
AMA/ABS/ANCC/ACPE Activity
Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO is a roundtable discussion between leading experts to inform and guide the safety and efficacy of trophoblast cell-surface antigen-directed antibody-drug conjugates (TROP2-directed ADCs) in different settings of non-small cell lung cancer (NSCLC) treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.

This activity is supported by downloadable slides that have the key discussion and teaching points.
Review the activity and claim AMA/ABS/ANCC/ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.




Benjamin Levy, MD Benjamin Levy, MD
Associate Professor of Oncology
Johns Hopkins Medicine

Aaron Lisberg, MD Aaron Lisberg, MD
Assistant Professor of Clinical Medicine
University of California, Los Angeles

 Alexander Spira, MD, PhD, FACP Alexander Spira, MD, PhD, FACP
Co-Director
Virginia Cancer Specialists Research Institute

20
Supported by an independent educational grant from
Gilead Sciences, Inc.

Launch Date: December 27, 2023
Release Date: December 27, 2023
Expiration Date: November 30, 2024

November 30, 2024
Mini Module
7676
Conversations_AdvancedNSCLC(1730x162).png
Hematology-Oncology

CookieConsent

Change Settings